Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer
Efficacy of Dovitinib for Squamous NSCLC.
Squamous NSCLC
DRUG: Dovitinib
response rate, 6 months
Efficacy of Dovitinib for Squamous NSCLC.